MX2013001361A - 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. - Google Patents

4-(1h-indol-3-il) - pirimidina como inhibidores de alk.

Info

Publication number
MX2013001361A
MX2013001361A MX2013001361A MX2013001361A MX2013001361A MX 2013001361 A MX2013001361 A MX 2013001361A MX 2013001361 A MX2013001361 A MX 2013001361A MX 2013001361 A MX2013001361 A MX 2013001361A MX 2013001361 A MX2013001361 A MX 2013001361A
Authority
MX
Mexico
Prior art keywords
pyrimidines
indol
alk inhibitors
formula
methods
Prior art date
Application number
MX2013001361A
Other languages
English (en)
Inventor
Brian Aquila
Timothy Pontz
Bo Peng
Victor Kamhl
Jamal Carlos Saeh
Kumar Thakur
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2013001361A publication Critical patent/MX2013001361A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide

Abstract

La presente invención se refiere a compuestos de Fórmula (I) y/o Fórmula (la): (Ver Formulas) y a sus sales, composiciones farmacéuticas, métodos de empleo y métodos para su preparación. Estos compuestos inhiben la actividad cinasa de ALK y, por lo tanto, se pueden utilizar para tratar el cáncer.
MX2013001361A 2010-08-02 2011-08-02 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. MX2013001361A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36991710P 2010-08-02 2010-08-02
US37205510P 2010-08-09 2010-08-09
US39094410P 2010-10-07 2010-10-07
PCT/GB2011/051465 WO2012017239A2 (en) 2010-08-02 2011-08-02 Chemical compounds

Publications (1)

Publication Number Publication Date
MX2013001361A true MX2013001361A (es) 2013-05-17

Family

ID=45527326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001361A MX2013001361A (es) 2010-08-02 2011-08-02 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.

Country Status (14)

Country Link
US (1) US8461170B2 (es)
EP (1) EP2601186A2 (es)
JP (1) JP2013534221A (es)
KR (1) KR20130096241A (es)
CN (1) CN103153982A (es)
AR (1) AR089550A1 (es)
AU (1) AU2011287386A1 (es)
BR (1) BR112013002587A2 (es)
CA (1) CA2805827A1 (es)
MX (1) MX2013001361A (es)
RU (1) RU2013109132A (es)
TW (1) TW201219383A (es)
UY (1) UY33539A (es)
WO (1) WO2012017239A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3333161T1 (sl) 2011-07-27 2020-07-31 Astrazeneca Ab Derivati 2-(2,4,5-substituiranega-anilino) pirimidina, kot modulatorji EGFR uporabni za zdravljenje raka
CN102899882B (zh) * 2012-11-07 2014-08-06 西南大学 超亲水涤纶织物的磷酸制备方法
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CN105085550B (zh) * 2014-05-21 2017-05-24 海门慧聚药业有限公司 一类alk激酶抑制剂及其制备方法
BR112016029662B1 (pt) * 2014-06-19 2023-10-24 Takeda Pharmaceutical Company Limited COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO
AU2015407300B2 (en) * 2015-08-31 2019-06-20 Wuxi Shuangliang Biotechnology Co., Ltd. 2-Arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof
CN106810553B (zh) * 2015-11-30 2020-03-17 江苏正大丰海制药有限公司 3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
WO2017205459A1 (en) 2016-05-26 2017-11-30 Kalyra Pharmaceuticals, Inc. Egfr inhibitor compounds
DK3514153T3 (da) * 2017-01-26 2021-09-27 Hanmi Pharm Ind Co Ltd Pyrimidinforbindelse og farmaceutisk anvendelse deraf
US11931536B2 (en) * 2017-07-26 2024-03-19 Dk Medical Technology Co., Ltd. Surface liquefied drug-coated balloon
CA3096790C (en) * 2018-04-09 2024-03-19 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
CN116763792B (zh) * 2023-06-19 2024-03-12 西安国际医学中心医院 Hg-14-10-04在制备治疗食管鳞癌的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
BRPI0620196A2 (pt) 2005-12-23 2013-01-15 Astrazeneca Ab composto, processo para a preparaÇço do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para a produÇço de um efeito antibacteriano em um animal de sangue quente, para a inibiÇço de dna girase e/ou topoisomerase iv bacteriana em um animal de sangue quente e para o tratamento de uma infecÇço bacteriana em um animal de sangue quente
US20100267707A1 (en) * 2006-06-22 2010-10-21 Merck Sharp & Dohme Corp. Tyrosine Kinase Inhibitors
ES2400619T3 (es) * 2007-06-01 2013-04-11 Glaxosmithkline Llc Inhibidores de imidazopiridina quinasa
CN103298814A (zh) * 2007-08-23 2013-09-11 阿斯利康(瑞典)有限公司 作为治疗增殖性疾病的ttk/mps1抑制剂的2-苯胺基嘌呤-8-酮
UY32203A (es) * 2008-10-29 2010-05-31 Astrazeneca Ab Amino pirimidinas y su uso en terapia

Also Published As

Publication number Publication date
US20120028924A1 (en) 2012-02-02
BR112013002587A2 (pt) 2019-09-24
KR20130096241A (ko) 2013-08-29
AU2011287386A1 (en) 2013-03-07
CA2805827A1 (en) 2012-02-09
UY33539A (es) 2012-02-29
AR089550A1 (es) 2014-09-03
JP2013534221A (ja) 2013-09-02
WO2012017239A2 (en) 2012-02-09
RU2013109132A (ru) 2014-09-10
TW201219383A (en) 2012-05-16
CN103153982A (zh) 2013-06-12
US8461170B2 (en) 2013-06-11
EP2601186A2 (en) 2013-06-12
WO2012017239A3 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
MX2012013197A (es) Inhibidores de indazol de cinasa.
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2013012981A (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
NZ700283A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
IN2014CN04530A (es)
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
TN2012000370A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal